> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# ARK's CRISPR Therapeutics Stake Is 10.4% — Its Innovation ETF Has An Interest Above 5%
- URL: https://www.bullished.co/arks-crispr-therapeutics-stake-is-10-4-its-innovation-etf-has-an-interest-above-5-f5d6eb06/
- Published: 2026-11-13T18:01:59.000Z
- Updated: 2026-11-13T18:01:59.000Z
- Description: The investment manager and Catherine D. Wood reported the same shares, with different voting and disposal powers.
- Author: Matteo Parrino
- Tags: SEC Filings, CRSP, Industry: Healthcare, Topic: Ownership & Activism

ARK Investment Management reported a [10.4% stake](https://www.sec.gov/Archives/edgar/data/0001697748/000110465926126825/xslSCHEDULE%5F13G%5FX01/primary%5Fdoc.xml?ref=bullished.co) in [CRISPR Therapeutics](https://www.bullished.co/tag/crsp/), which develops gene-based treatments for serious diseases, in a passive ownership disclosure filed Friday. The position covered September 30, 2026, and ARK identified its ARK Innovation ETF as having a client interest above 5%.

## One Position, Different Ownership Powers

ARK reported 10,056,844 common shares. Catherine D. Wood, ARK's chief executive and chief investment officer, reported beneficial ownership of that same position; her entry does not add another block of shares to ARK's total.

ARK had sole authority to vote 9,466,222 shares and shared authority over 143,106\. Wood reported shared voting authority over 9,609,328 shares, with none under her sole authority.

The disposal powers followed a different split: ARK reported sole authority to dispose of all 10,056,844 shares, while Wood reported shared disposal authority over the full position.

ARK certified that the shares were held for ordinary business activity and [not to influence](https://www.sec.gov/Archives/edgar/data/0001697748/000110465926126825/xslSCHEDULE%5F13G%5FX01/primary%5Fdoc.xml?ref=bullished.co) the company's control. ARK Innovation ETF was the client identified as exceeding the 5% interest threshold.

ARK's concentrated ETF holdings in small and mid-sized companies have led to about 170 ownership schedules over two years.

## The Gene-Editing Business Behind CRSP

CRISPR Therapeutics uses CRISPR/Cas9 editing to change targeted DNA sequences. Its programs cover blood disorders, editing delivered directly into the body, CAR T cell therapies and regenerative medicine for Type 1 diabetes.

Its most advanced product, CASGEVY, treats eligible patients with severe sickle cell disease or transfusion-dependent beta thalassemia. CRISPR develops and sells the treatment jointly with Vertex Pharmaceuticals, which leads commercialization.

CASGEVY has approval in the United States, the European Union, Great Britain, Canada, Switzerland and several Middle Eastern countries. CRISPR also works with Sirius Therapeutics on siRNA medicines and operates its own manufacturing facility in Framingham, Massachusetts.

CRISPR Therapeutics had a market capitalization of $4.1 billion in Friday trading as of 12:55 p.m. ET.

Learn

- [13D Filing Requirements And Deadline, Shown With Real Filings →](https://www.bullished.co/learn/13d-filing-requirements/)  
A Schedule 13D is required when you own more than 5% of a public company's voting shares. See the deadline, contents and real filings from this week.
- [13D Vs 13G: What Each 5% Stake Filing Means And How To Read One →](https://www.bullished.co/learn/13d-vs-13g/)  
13D vs 13G: both report stakes above 5%, but 13G is the short passive form and 13D explains intent. See real BlackRock and Pictet filings read in plain English.

### Sources

- [SCHEDULE 13G/A — ARK Investment Management LLC re: CRISPR Therapeutics AG (CRSP)](https://www.sec.gov/Archives/edgar/data/0001697748/000110465926126825/xslSCHEDULE%5F13G%5FX01/primary%5Fdoc.xml?ref=bullished.co) — SEC EDGAR
- [SCHEDULE 13G/A Exhibit 1 — EXHIBIT 1](https://www.sec.gov/Archives/edgar/data/1697748/000110465926126825/tm2629184d5%5Fex1.htm?ref=bullished.co) — SEC EDGAR

### More on CRISPR Therapeutics

- [State Street Holds 5.2% Of CRISPR Therapeutics Without Seeking To Influence Control](https://www.bullished.co/state-street-holds-5-2-of-crispr-therapeutics-without-seeking-to-influence-control-3a49092f/)
- [CRISPR Therapeutics' $12.7 Million Quarter Rests On A Vertex Option That Vertex Passed On](https://www.bullished.co/crispr-therapeutics-12-7-million-quarter-rests-on-a-vertex-option-that-vertex-passed-on-d639f72b/)
- [Casgevy Sales Hit $99 Million, Nearly Six Times Last Year, As CRISPR's Loss Widens To $111.4 Million](https://www.bullished.co/casgevy-sales-hit-99-million-nearly-six-times-last-year-as-crisprs-loss-widens-to-111-4-fec54452/)

[All CRISPR Therapeutics (CRSP) coverage →](https://www.bullished.co/tag/crsp/)